In what can potentially be a gamechanger in treating Alzheimer’s disease, scientists at the Technical University of Munich (TUM) has unveiled the root cause of the disease.

Can Alzheimer's disease be reversed? Groundbreaking new treatment

<p>What does a brain affected by Alzheimer's disease look like? More specifically, how do the proteins present in the brains of Dementia and Alzheimer's disease patients appear? A clear view of the structures of these proteins will enable scientists to find a cure for these diseases affecting millions of people.</p>

<p>Now for the first time, with the help of 3D imaging, scientists at the UK's Leeds University have revealed the molecular structures of the two key proteins present in brains affected by Alzheimer's and dementia.</p>

<p>These proteins are β-amyloid and tau, which form plaques and abnormal filaments in the brain that lead to dementia and Alzheimer's disease, the most common ailments of memory loss and cognitive impairment. While it is not conclusively proven that these proteins are the only cause of the two diseases, they have been present in brains affected by Dementia and Alzheimer's disease.</p>

<p>"In the longer term, it is hoped that observing this interplay of proteins within tissues will accelerate identifying new targets for next-generation mechanism-based therapeutics and diagnostics," Leeds University said in a release on the study, which was published in Nature Journal.</p>

<p><strong>Also read:&nbsp;<a href="https://www.wionews.com/entertainment/lifestyle/news-how-menstrual-cycle-affect-your-mood-and-behaviour-medical-expert-answers-746973">How menstrual cycle affects your mood and behaviour? Medical expert answers</a></strong></p>

<p>The study is part of efforts to understand the environment in which these proteins exist and find out how they interact with surrounding cells and tissues, specifically those affected by Alzheimer's and Dementia.</p>

<p>To explore deep inside an Alzheimer’s disease brain, scientists created 3D maps using cryo-electron tomography and fluorescence microscopy.&nbsp;</p>

<p>With these 3D maps, they could "observe proteins, the molecular building blocks of life a million times smaller than a grain of rice, within the brain," said the release from Leeds University. "This study revealed the molecular structure of tau in tissue, how amyloids are arranged, and new molecular structures entangled within this pathology in the brain."</p>

<p><strong>Also watch:&nbsp;<a href="https://www.wionews.com/videos/cancer-rates-among-under-50s-risen-24-since-1995-why-are-so-many-young-adults-getting-the-disease-728246">Cancer rates among under 50s risen 24% since 1995, why are so many young adults getting the disease?</a></strong></p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/cancer-rates-among-under-50s-risen-24-since-1995-why-are-so-many-young-adults-getting-the-disease-728246/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

<p>β-amyloid plaques and tau filaments disrupt cellular communication, causing memory loss and confusion, and eventual death of healthy cells.</p>

<p>"This first glimpse of the structure of molecules inside the human brain offers further clues to what happens to proteins in Alzheimer’s disease but also sets out an experimental approach that can be applied to better understand a broad range of other devastating neurological diseases," said Dr Rene Frank, lead author of the study and Associate Professor, School of Biomedical Sciences at Leeds University.</p>

<p>This study was done in&nbsp;collaboration with Amsterdam UMC, Zeiss Microscopy, and the University of Cambridge.&nbsp;</p>

<p><em>(With inputs from agencies)</em></p>


What does a brain affected by Alzheimer's disease look like? More specifically, how do the proteins present in the brains of Dementia and Alzheimer's disease patients appear?

What does a brain affected by Alzheimer's disease look like? More specifically, how do the proteins present in the brains of Dementia and Alzheimer's disease patients appear? A clear view of the structures of these proteins will enable scientists to find a cure for these diseases affecting millions of people. Now for the first time, with the help of 3D imaging, scientists at the UK's Leeds University have revealed the molecular structures of the two key proteins present in brains affected by Alzheimer's and dementia. These proteins are β-amyloid and tau, which form plaques and abnormal filaments in the brain that lead to dementia and Alzheimer's disease, the most common ailments of memory loss and cognitive impairment. While it is not conclusively proven that these proteins are the only cause of the two diseases, they have been present in brains affected by Dementia and Alzheimer's disease. "In the longer term, it is hoped that observing this interplay of proteins within tissues will accelerate identifying new targets for next-generation mechanism-based therapeutics and diagnostics," Leeds University said in a release on the study, which was published in Nature Journal. Also read: How menstrual cycle affects your mood and behaviour? Medical expert answers The study is part of efforts to understand the environment in which these proteins exist and find out how they interact with surrounding cells and tissues, specifically those affected by Alzheimer's and Dementia. To explore deep inside an Alzheimer’s disease brain, scientists created 3D maps using cryo-electron tomography and fluorescence microscopy. With these 3D maps, they could "observe proteins, the molecular building blocks of life a million times smaller than a grain of rice, within the brain," said the release from Leeds University. "This study revealed the molecular structure of tau in tissue, how amyloids are arranged, and new molecular structures entangled within this pathology in the brain." Also watch: Cancer rates among under 50s risen 24% since 1995, why are so many young adults getting the disease? β-amyloid plaques and tau filaments disrupt cellular communication, causing memory loss and confusion, and eventual death of healthy cells. "This first glimpse of the structure of molecules inside the human brain offers further clues to what happens to proteins in Alzheimer’s disease but also sets out an experimental approach that can be applied to better understand a broad range of other devastating neurological diseases," said Dr Rene Frank, lead author of the study and Associate Professor, School of Biomedical Sciences at Leeds University. This study was done in collaboration with Amsterdam UMC, Zeiss Microscopy, and the University of Cambridge. (With inputs from agencies)

A deep look inside Alzheimer's brain: Molecule structure of proteins unveiled for first time

<p>Researchers at Cambridge University in the UK have shown that an Artificial Intelligence model created by them can predict whether people with early signs of dementia will remain stable or develop Alzheimer’s disease. The AI model managed to make accurate predictions in four out of five cases, which is three times better than in clinical trials.</p>

<h2><strong>How significant is use of AI in predicting Alzheimer's and dementia onset?</strong></h2>

<p>Costly and often dangerous procedures are requited to detect dementia and Alzheimer's. Non-invasive methods like this AI tool will help in avoiding misdiagnosis.</p>

<p><strong>Also read:</strong>&nbsp;<a data-ctorig="https://www.wionews.com/entertainment/lifestyle/news-explained-is-forgetfulness-a-key-indicator-of-alzheimers-disease-experts-tell-when-to-seek-help-733275" data-cturl="https://www.google.com/url?client=internal-element-cse&amp;cx=006054055338965708568:09spwrlibei&amp;q=https://www.wionews.com/entertainment/lifestyle/news-explained-is-forgetfulness-a-key-indicator-of-alzheimers-disease-experts-tell-when-to-seek-help-733275&amp;sa=U&amp;ved=2ahUKEwiZy6zZsNOHAxUjd2wGHZpxEXQQFnoECAAQAg&amp;usg=AOvVaw2wa6vf9HrmV4PMmBEnpUvH&amp;arm=e" dir="ltr" href="https://www.wionews.com/entertainment/lifestyle/news-explained-is-forgetfulness-a-key-indicator-of-alzheimers-disease-experts-tell-when-to-seek-help-733275" target="_blank">Explained: Is forgetfulness a key indicator of&nbsp;<b>Alzheimer's</b>&nbsp;disease</a></p>

<p>The Cambridge team said in a release that the new method "could reduce the need for invasive and costly diagnostic tests while improving treatment outcomes early when interventions such as lifestyle changes or new medicines may have a chance to work best."</p>

<p>Finding out Alzheimer's in earl stage can be crucial in its management and treatment.</p>

<h2><strong>How it was done: AI model predicts onset of dementia and Alzheimer's disease</strong></h2>

<p>The AI model was created using data cohort of some 400 patients in the US, from their cognitive tests and structural MRI scans showing grey matter atrophy, the Cambridge University release said.&nbsp;</p>

<p>The AI model distinguished between people with stable mild cognitive impairment and those who progressed to Alzheimer’s disease within a three-year period.&nbsp;It accurately identified individuals who went on to develop Alzheimer’s in 82% of cases. It also idenfitied those who didn’t develop symptoms in 81% from cognitive tests and an MRI scan alone.</p>

<p><strong>Video:&nbsp;European medicines watchdog rejects new Alzheimer's drug</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/european-medicines-watchdog-rejects-new-alzheimers-drug-744701/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>

<p>"We’ve created a tool which is much more sensitive than current approaches at predicting whether someone will progress from mild symptoms to Alzheimer’s," said Zoe Kourtzi of Cambridge University in the release.</p>

<p><strong>What is Dementia? What is Alzheimer's Disease?&nbsp;</strong></p>

<p>Dementia is a series of conditions involving memory loss, cognitive degeneration that affects more than 55 million people annually.</p>

<p><strong>Also read:&nbsp;</strong><a data-ctorig="https://www.wionews.com/trending/world-alzheimers-day-2023-history-significance-theme-and-early-symptoms-of-alzheimers-disease-638118" data-cturl="https://www.google.com/url?client=internal-element-cse&amp;cx=006054055338965708568:09spwrlibei&amp;q=https://www.wionews.com/trending/world-alzheimers-day-2023-history-significance-theme-and-early-symptoms-of-alzheimers-disease-638118&amp;sa=U&amp;ved=2ahUKEwiZy6zZsNOHAxUjd2wGHZpxEXQQFnoECAkQAg&amp;usg=AOvVaw2gjo4LuZhPNVoMWnPVBk7G&amp;arm=e" dir="ltr" href="https://www.wionews.com/trending/world-alzheimers-day-2023-history-significance-theme-and-early-symptoms-of-alzheimers-disease-638118" target="_blank">World&nbsp;<b>Alzheimer's</b>&nbsp;Day : History, significance, theme</a></p>

<p>The main cause of dementia is Alzheimer’s disease, which accounts for 60-80% of cases.&nbsp;</p>

<p><em>(With inputs from agencies)</em><br />
&nbsp;</p>


Researchers at Cambridge University in the UK have shown that an Artificial Intelligence model created by them can predict whether people with early signs of dementia will remain stable or develop Alzheimer’s disease.

Researchers at Cambridge University in the UK have shown that an Artificial Intelligence model created by them can predict whether people with early signs of dementia will remain stable or develop Alzheimer’s disease. The AI model managed to make accurate predictions in four out of five cases, which is three times better than in clinical trials. How significant is use of AI in predicting Alzheimer's and dementia onset? Costly and often dangerous procedures are requited to detect dementia and Alzheimer's. Non-invasive methods like this AI tool will help in avoiding misdiagnosis. Also read: Explained: Is forgetfulness a key indicator of Alzheimer's disease The Cambridge team said in a release that the new method "could reduce the need for invasive and costly diagnostic tests while improving treatment outcomes early when interventions such as lifestyle changes or new medicines may have a chance to work best." Finding out Alzheimer's in earl stage can be crucial in its management and treatment. How it was done: AI model predicts onset of dementia and Alzheimer's disease The AI model was created using data cohort of some 400 patients in the US, from their cognitive tests and structural MRI scans showing grey matter atrophy, the Cambridge University release said. The AI model distinguished between people with stable mild cognitive impairment and those who progressed to Alzheimer’s disease within a three-year period. It accurately identified individuals who went on to develop Alzheimer’s in 82% of cases. It also idenfitied those who didn’t develop symptoms in 81% from cognitive tests and an MRI scan alone. Video: European medicines watchdog rejects new Alzheimer's drug × "We’ve created a tool which is much more sensitive than current approaches at predicting whether someone will progress from mild symptoms to Alzheimer’s," said Zoe Kourtzi of Cambridge University in the release. What is Dementia? What is Alzheimer's Disease? Dementia is a series of conditions involving memory loss, cognitive degeneration that affects more than 55 million people annually. Also read: World Alzheimer's Day : History, significance, theme The main cause of dementia is Alzheimer’s disease, which accounts for 60-80% of cases. (With inputs from agencies)

AI tool predicts Alzheimer's disease onset better than clinical trials. Here is how it works

<p>Do you love your bacon? Then take note: a new study has suggested that eating processed food can add to dementia risk. The study is based on some 130,000 subjects whose eating habits were tracked by US researchers over 40 years.</p>

<h2><strong>What did the study find?</strong></h2>

<p>The study was done on 130,000 health workers including nurses over a period of 43 years. Their diet information was tracked every 2-4 years with questions like how much of bacons, hot dogs, sausages, salami and sandwich meat they had in this period, The Guardian said in a report.</p>

<p>The study, presented to an Alzheimer’s Association conference in the US recently, found that 11,000 participants developed dementia during the follow-up.</p>

<p>The Guardian, citing the research, said that two servings of processed red meat per week raised cognitive decline risk by 14 per cent in the study subjects, as opposed to three servings per month.</p>

<p><strong>Also read:&nbsp;<a data-ved="2ahUKEwjV16e3odGHAxWJkq8BHfffAH8QxfQBKAB6BAgPEAE" href="https://www.wionews.com/science/frequently-nose-picking-leading-cause-of-progressive-dementia-study-687765" jsname="YKoRaf" ping="/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.wionews.com/science/frequently-nose-picking-leading-cause-of-progressive-dementia-study-687765&amp;ved=2ahUKEwjV16e3odGHAxWJkq8BHfffAH8QxfQBKAB6BAgPEAE">Frequent nose-picking leading cause of progressive dementia: Study - Science News</a></strong><br />
<br />
"By studying people over a long period of time, we found that eating processed red meat could be a significant risk factor for dementia,” said lead author Dr Yuhan Li, an assistant professor at the Brigham and Women’s hospital in Boston.</p>

<p>Li, who conducted the study at the Harvard TH Chan school of public health in Boston recommended that dietary guidelines should include recommendations to promote brain health.</p>

<h2><strong>How to reduce risk of dementia if you love processed red meat</strong></h2>

<p>According to the study, risk of dementia can be reduced by a good 23 per cent if one replaces one daily serving of processed red meat with nuts, beans or tofu, The Guardian report said. The risk can also be reduced if processed red meat is consumed along with nuts, beans or tofu.&nbsp;</p>

<p>Processed red meat had already been linked to risks of cancer, heart disease and type 2 diabetes.</p>

<h2><strong>What is dementia?</strong></h2>

<p>The Alzheimers' Association defines dementia as&nbsp;"a general term for&nbsp;loss of memory, language, problem-solving and other thinking abilities that are severe&nbsp;enough to interfere with daily life." It is not a specific disease but a set of debilitating conditions involving cognitive decline, often associated with age.</p>

<p><strong>Watch:&nbsp;Gravitas: Does body composition affect risk for dementia?</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-does-body-composition-affect-risk-for-dementia-744231/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>According to World Health Organization,&nbsp;more than 55 million people have dementia worldwide. Every year, there are nearly 10 million new cases, as per the UN health agency.</p>

<p>There will be an estimated 153 million people living with dementia by 2050, a three-fold rise from current levels.</p>

<p><em>(With inputs from agencies)</em></p>


Do you love your bacon? Then take note: a new study has suggested that eating processed food can add to dementia risk. The study is based on some 130,000 subjects whose eating habits were tracked by US researchers over 40 years.

Do you love your bacon? Then take note: a new study has suggested that eating processed food can add to dementia risk. The study is based on some 130,000 subjects whose eating habits were tracked by US researchers over 40 years. What did the study find? The study was done on 130,000 health workers including nurses over a period of 43 years. Their diet information was tracked every 2-4 years with questions like how much of bacons, hot dogs, sausages, salami and sandwich meat they had in this period, The Guardian said in a report. The study, presented to an Alzheimer’s Association conference in the US recently, found that 11,000 participants developed dementia during the follow-up. The Guardian, citing the research, said that two servings of processed red meat per week raised cognitive decline risk by 14 per cent in the study subjects, as opposed to three servings per month. Also read: Frequent nose-picking leading cause of progressive dementia: Study - Science News "By studying people over a long period of time, we found that eating processed red meat could be a significant risk factor for dementia,” said lead author Dr Yuhan Li, an assistant professor at the Brigham and Women’s hospital in Boston. Li, who conducted the study at the Harvard TH Chan school of public health in Boston recommended that dietary guidelines should include recommendations to promote brain health. How to reduce risk of dementia if you love processed red meat According to the study, risk of dementia can be reduced by a good 23 per cent if one replaces one daily serving of processed red meat with nuts, beans or tofu, The Guardian report said. The risk can also be reduced if processed red meat is consumed along with nuts, beans or tofu. Processed red meat had already been linked to risks of cancer, heart disease and type 2 diabetes. What is dementia? The Alzheimers' Association defines dementia as "a general term for loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life." It is not a specific disease but a set of debilitating conditions involving cognitive decline, often associated with age. Watch: Gravitas: Does body composition affect risk for dementia? × According to World Health Organization, more than 55 million people have dementia worldwide. Every year, there are nearly 10 million new cases, as per the UN health agency. There will be an estimated 153 million people living with dementia by 2050, a three-fold rise from current levels. (With inputs from agencies)

Do you love your bacon? Eating processed red meat can add to your dementia risk, suggests large study

<p>A revolutionary&nbsp;new blood test can detect if a patient is suffering from memory loss due to Alzheimer's disease, with 90 per cent accuracy. The convenience of a blood test means that patients can receive accurate diagnoses without splurging extra cash on&nbsp;current diagnostic methods where expensive scans and spinal fluid samples are used.&nbsp;</p>

<p>Comparatively, neurologists and memory specialists are able to correctly diagnose Alzheimer's in only 73 per cent of their cases. As for primary care doctors, the figure further plummets to only a 61 per cent accuracy rate.&nbsp;</p>

<p>Researchers at Lund University in Sweden published the study in <em>JAMA, </em>titled, "Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care" on Sunday (Jul 28).</p>

<p>To conduct the blood test, the scientists attempted to evaluate a combination of protein ratios&nbsp;found in human serum that can accurately detect the disease. The test measures&nbsp;tau protein 217 (or p-tau217 for short) and amyloid - both of which&nbsp;are biomarkers used to detect mild cognitive impairment and early-stage Alzheimer’s disease.</p>

<p>In some countries, in order to receive medicines for Alzheimer's, the patient needs to prove that they have an accumulation of amyloids in their brain. Accumulation of amyloids is one of the indicators of Alzheimer's disease which the blood test conducted by researchers at Lund University attempted to find.&nbsp;</p>

<p>“Increases in p tau-217 concentrations in the blood are quite profound in Alzheimer’s disease. At the dementia stage of the disease, levels are more than 8 times higher compared with elderly without Alzheimer’s,”&nbsp;study coauthor Dr Sebastian Palmqvist was quoted as saying by <em>CNN.&nbsp;</em></p>

<p><a href="https://www.wionews.com/videos/european-medicines-watchdog-rejects-new-alzheimers-drug-744701"><strong>Watch |&nbsp;European medicines watchdog rejects new Alzheimer's drug</strong></a></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/european-medicines-watchdog-rejects-new-alzheimers-drug-744701/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<h2><strong>Reliability of blood test</strong></h2>

<p>To confirm whether the blood test was reliable or not,&nbsp;Palmqvist and his team zeroed in on 1213 patients who were being evaluated for Alzheimer's by their family doctors or specialists between February 2020 and January 2024. As it turns out, the blood test predicts Alzheimer's with a 90 per cent accuracy.&nbsp;</p>

<p>"This blood test (the APS2) had high diagnostic accuracy for identifying Alzheimer's disease among individuals with cognitive symptoms in primary and secondary care, providing superior performance compared with the diagnostic accuracy after standard clinical evaluation," the test results showed.&nbsp;</p>

<p><a href="https://www.wionews.com/science/us-fda-approves-new-breakthrough-medicine-for-alzheimers-heres-what-it-does-550175"><strong>Also read |&nbsp;US FDA approves new ‘breakthrough’ medicine for Alzheimer’s. Here’s what it does</strong></a></p>

<p>Once fully vetted, highly accurate blood tests could change the game in the speed in which doctors can conduct Alzheimer’s trials and get to the next new medication.&nbsp;</p>

<p><em>(With inputs from agencies)</em></p>


A revolutionary new blood test can detect if a patient is suffering from memory loss due to Alzheimer's disease, with 90 per cent accuracy. The convenience of a blood test means that patients can receive accurate diagnoses without splurging extra cash on current diagnostic methods where expensive scans and spinal fluid samples are used.

A revolutionary new blood test can detect if a patient is suffering from memory loss due to Alzheimer's disease, with 90 per cent accuracy. The convenience of a blood test means that patients can receive accurate diagnoses without splurging extra cash on current diagnostic methods where expensive scans and spinal fluid samples are used. Comparatively, neurologists and memory specialists are able to correctly diagnose Alzheimer's in only 73 per cent of their cases. As for primary care doctors, the figure further plummets to only a 61 per cent accuracy rate. Researchers at Lund University in Sweden published the study in JAMA, titled, "Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care" on Sunday (Jul 28). To conduct the blood test, the scientists attempted to evaluate a combination of protein ratios found in human serum that can accurately detect the disease. The test measures tau protein 217 (or p-tau217 for short) and amyloid - both of which are biomarkers used to detect mild cognitive impairment and early-stage Alzheimer’s disease. In some countries, in order to receive medicines for Alzheimer's, the patient needs to prove that they have an accumulation of amyloids in their brain. Accumulation of amyloids is one of the indicators of Alzheimer's disease which the blood test conducted by researchers at Lund University attempted to find. “Increases in p tau-217 concentrations in the blood are quite profound in Alzheimer’s disease. At the dementia stage of the disease, levels are more than 8 times higher compared with elderly without Alzheimer’s,” study coauthor Dr Sebastian Palmqvist was quoted as saying by CNN. Watch | European medicines watchdog rejects new Alzheimer's drug × Reliability of blood test To confirm whether the blood test was reliable or not, Palmqvist and his team zeroed in on 1213 patients who were being evaluated for Alzheimer's by their family doctors or specialists between February 2020 and January 2024. As it turns out, the blood test predicts Alzheimer's with a 90 per cent accuracy. "This blood test (the APS2) had high diagnostic accuracy for identifying Alzheimer's disease among individuals with cognitive symptoms in primary and secondary care, providing superior performance compared with the diagnostic accuracy after standard clinical evaluation," the test results showed. Also read | US FDA approves new ‘breakthrough’ medicine for Alzheimer’s. Here’s what it does Once fully vetted, highly accurate blood tests could change the game in the speed in which doctors can conduct Alzheimer’s trials and get to the next new medication. (With inputs from agencies)

Revolutionary new blood test can detect Alzheimer's with 90% accuracy

<p>An FDA advisory panel on Monday unanimously agreed that Eli Lilly's Alzheimer's drug, donanemab, has potential benefits for early-stage patients that outweigh the risks. They also confirmed positive effects from trial data on slowing the disease's progression.</p>

<p>The vote clears the way for a final FDA decision on the treatment, which initially had been expected earlier this year before the agency called for the meeting so its independent panel of experts could weigh in.</p>

<p><strong>Also read:</strong>&nbsp;<a href="https://www.wionews.com/science/iit-indore-study-reveals-early-diagnosis-of-alzheimers-possible-with-advanced-ai-techniques-717956">IIT Indore study reveals early diagnosis of Alzheimer's possible with advanced AI techniques</a></p>

<p>"We really are pleased that the advisory committee recognized donanemab's strong positive benefit risk," Dawn Brooks, Lilly's development leader for donanemab, said in an interview after the vote.</p>

<p>Now with the panel's unanimous support, the company looks forward to the FDA finishing its review, she said.</p>

<p>The agency is not obligated to follow the recommendations of its outside advisers, but typically does so.</p>

<p>In its discussion, the FDA had asked the panel to consider some unique aspects of Lilly's trial, which differed significantly from the trial design of Eisai and Biogen Leqembi, which won U.S. approval after going through a similar advisory committee meeting.</p>

<p>Both drugs are designed to remove toxic beta amyloid plaques from the brains of people with early Alzheimer's disease.</p>

<p>The antibody treatments, which succeeded in slowing disease progression in clinical trials, follow three decades of failed attempts to find drugs to fight the fatal mind-wasting disease.</p>

<p>A key difference in trial design for the two treatments is that Lilly measured levels of a second Alzheimer's-related protein called tau associated with brain cell death to select patients most likely to show a benefit within the study's 76-week trial period.</p>

<p>As a result, Lilly excluded patients with very low or no levels of tau from the pivotal trial, but they did a separate analysis in this group from another fairly large study to see if the drug resulted in underlying changes.</p>

<p><strong>Also read |&nbsp;<a href="https://www.wionews.com/science/strong-link-found-between-alzheimers-disease-and-intake-of-processed-food-study-686418">Strong link found between Alzheimer's disease and intake of processed food: Study</a></strong></p>

<p>Several panelists noted that that data was likely suggestive of a treatment benefit.</p>

<p>Panelists also largely agreed that testing for tau should not be required before treatment, noting that such testing was not widely available and could reduce access to rural or underserved populations.</p>

<p>Several panel members noted there were elevated safety issues for people who have two copies of the APOE4 gene that is associated with a higher risk of Alzheimer's. They suggested that doctors prescribing the drug need to be educated on the heightened risk and discuss that with patients.</p>

<p>In Lilly's large clinical trial, donanemab, given by infusion once a month, slowed progression of memory and thinking problems by 29% overall, roughly comparable to the 27% slowing seen with Leqembi.</p>

<p>Brain swelling and bleeding - a known risk for this class of drugs - occurred in 24% and 31%, respectively for those taking donanemab and three patients died.</p>

<p>In Eisai and Biogen's late-stage study, 12.6% of participants taking Leqembi experienced brain swelling and 17.3% brain bleeding.</p>

<p>Leqembi was approved with the agency's strongest "boxed" warning about the risk of potentially dangerous brain swelling and bleeding that applies to all drugs in the class.</p>

<p>Several panel members commended Lilly's innovative trial design, which allowed participants to stop treatment as soon as brain imaging showed the amyloid plaque was cleared, but they said it could make the treatment harder for doctors to know when to withdraw treatment, and when to restart it if needed.</p>

<p>Lilly said it is planning trials to test the treatment in patients genetically predisposed to develop Alzheimer's, including people with Down syndrome.</p>

<p><strong>Also read:&nbsp;<a data-jsarwt="1" data-usg="AOvVaw3sYRGPMHjSWZUO5fJrPyYV" data-ved="2ahUKEwjQwKWI44yEAxUlUWwGHQ7eDHEQxfQBKAB6BAgHEAE" href="https://www.wionews.com/science/scientists-reveal-11-dementia-risk-factors-that-could-determine-who-all-are-at-risk-629154" jsname="YKoRaf">Scientists reveal 11 dementia risk factors that could determine who all are at risk</a></strong></p>

<p>Jefferies analyst Michael Yee said in a note to clients that the vote "sets up an eventual FDA approval," adding that having two players on the market would be a good thing longer-term.</p>

<p>Shares of the Indianapolis drugmaker closed up 1.8% at $865.</p>


An FDA advisory panel on Monday unanimously agreed that Eli Lilly's Alzheimer's drug, donanemab, has potential benefits for early-stage patients that outweigh the risks.

An FDA advisory panel on Monday unanimously agreed that Eli Lilly's Alzheimer's drug, donanemab, has potential benefits for early-stage patients that outweigh the risks. They also confirmed positive effects from trial data on slowing the disease's progression. The vote clears the way for a final FDA decision on the treatment, which initially had been expected earlier this year before the agency called for the meeting so its independent panel of experts could weigh in. Also read: IIT Indore study reveals early diagnosis of Alzheimer's possible with advanced AI techniques "We really are pleased that the advisory committee recognized donanemab's strong positive benefit risk," Dawn Brooks, Lilly's development leader for donanemab, said in an interview after the vote. Now with the panel's unanimous support, the company looks forward to the FDA finishing its review, she said. The agency is not obligated to follow the recommendations of its outside advisers, but typically does so. In its discussion, the FDA had asked the panel to consider some unique aspects of Lilly's trial, which differed significantly from the trial design of Eisai and Biogen Leqembi, which won U.S. approval after going through a similar advisory committee meeting. Both drugs are designed to remove toxic beta amyloid plaques from the brains of people with early Alzheimer's disease. The antibody treatments, which succeeded in slowing disease progression in clinical trials, follow three decades of failed attempts to find drugs to fight the fatal mind-wasting disease. A key difference in trial design for the two treatments is that Lilly measured levels of a second Alzheimer's-related protein called tau associated with brain cell death to select patients most likely to show a benefit within the study's 76-week trial period. As a result, Lilly excluded patients with very low or no levels of tau from the pivotal trial, but they did a separate analysis in this group from another fairly large study to see if the drug resulted in underlying changes. Also read | Strong link found between Alzheimer's disease and intake of processed food: Study Several panelists noted that that data was likely suggestive of a treatment benefit. Panelists also largely agreed that testing for tau should not be required before treatment, noting that such testing was not widely available and could reduce access to rural or underserved populations. Several panel members noted there were elevated safety issues for people who have two copies of the APOE4 gene that is associated with a higher risk of Alzheimer's. They suggested that doctors prescribing the drug need to be educated on the heightened risk and discuss that with patients. In Lilly's large clinical trial, donanemab, given by infusion once a month, slowed progression of memory and thinking problems by 29% overall, roughly comparable to the 27% slowing seen with Leqembi. Brain swelling and bleeding - a known risk for this class of drugs - occurred in 24% and 31%, respectively for those taking donanemab and three patients died. In Eisai and Biogen's late-stage study, 12.6% of participants taking Leqembi experienced brain swelling and 17.3% brain bleeding. Leqembi was approved with the agency's strongest "boxed" warning about the risk of potentially dangerous brain swelling and bleeding that applies to all drugs in the class. Several panel members commended Lilly's innovative trial design, which allowed participants to stop treatment as soon as brain imaging showed the amyloid plaque was cleared, but they said it could make the treatment harder for doctors to know when to withdraw treatment, and when to restart it if needed. Lilly said it is planning trials to test the treatment in patients genetically predisposed to develop Alzheimer's, including people with Down syndrome. Also read: Scientists reveal 11 dementia risk factors that could determine who all are at risk Jefferies analyst Michael Yee said in a note to clients that the vote "sets up an eventual FDA approval," adding that having two players on the market would be a good thing longer-term. Shares of the Indianapolis drugmaker closed up 1.8% at $865.

Alzheimer's drug donanemab gets unanimous backing from FDA advisory panel

<p><meta name="uuid" content="uuidOWrieHysxPRb" /></p>

<p>According to a new study, stressful life events like divorce or the loss of a loved one increase a person's chance of dementia in later life. But only if the traumatic experience occurred during youth or in middle age.</p>

<p>The research, published in Annals of Neurology, comprised 1,290 adults who were at high risk of acquiring Alzheimer's disease. The researchers examined 18 stressful life events and determined when they occurred in people's lives.</p>

<p>A subgroup of the group (393 people) had their spinal fluid samples taken to look for unusual proteins known as tau and amyloid that&nbsp;are linked&nbsp;to Alzheimer's disease. They also measured the amount of grey matter and searched for indicators of brain inflammation, which is assumed to be a factor in the illness.&nbsp;</p>

<p>Although the researchers discovered that stressful life experiences between childhood and midlife&nbsp;were linked&nbsp;to aberrant amyloid and tau, two "biological markers" of Alzheimer's disease, they&nbsp;were not&nbsp;linked&nbsp;to losses in grey matter.</p>

<p>The presence of Alzheimer's disease markers may imply that stress has a particularly significant influence on chemicals and reactions in the brain during childhood and middle age. Midlife is when Alzheimer's indicators begin to accumulate in the brain, which might explain why it is also a susceptible stage.</p>

<p><strong>Also read:&nbsp;<a href="https://www.wionews.com/science/face-of-stone-age-man-thought-to-have-drowned-4000-years-ago-reconstructed-721411">Face of Stone Age man thought to have drowned 4,000 years ago reconstructed</a></strong></p>

<p>Total stressful life experiences were similarly linked to amyloid biomarkers, brain inflammation, and reduced grey matter, but only in people with a history of psychiatric problems.</p>

<p>This&nbsp;might be because people with mental health concerns are more sensitive to the adverse effects of stress. It's also possible that people who have gone through certain stressful life situations are more prone to develop a psychiatric disorder. In either case, people who encounter both may face an elevated danger. Total stressful life experiences were not associated with Alzheimer's disease indicators in all individuals.</p>

<p>These findings imply that some periods or settings amplify the effects of stressful life events on the development of Alzheimer's disease-related brain alterations, at least in individuals who are predisposed to the disease.</p>

<p>There are certain limits to the results. The researchers depended on participants to recall what and when stressful situations occurred, often several years later.</p>

<p><em>(With inputs from agencies)</em></p>


According to a new study, stressful life events like divorce or the loss of a loved one increase a person's chance of dementia in later life. But only if the traumatic experience occurred during youth or in middle age.

According to a new study, stressful life events like divorce or the loss of a loved one increase a person's chance of dementia in later life. But only if the traumatic experience occurred during youth or in middle age. The research, published in Annals of Neurology, comprised 1,290 adults who were at high risk of acquiring Alzheimer's disease. The researchers examined 18 stressful life events and determined when they occurred in people's lives. A subgroup of the group (393 people) had their spinal fluid samples taken to look for unusual proteins known as tau and amyloid that are linked to Alzheimer's disease. They also measured the amount of grey matter and searched for indicators of brain inflammation, which is assumed to be a factor in the illness. Although the researchers discovered that stressful life experiences between childhood and midlife were linked to aberrant amyloid and tau, two "biological markers" of Alzheimer's disease, they were not linked to losses in grey matter. The presence of Alzheimer's disease markers may imply that stress has a particularly significant influence on chemicals and reactions in the brain during childhood and middle age. Midlife is when Alzheimer's indicators begin to accumulate in the brain, which might explain why it is also a susceptible stage. Also read: Face of Stone Age man thought to have drowned 4,000 years ago reconstructed Total stressful life experiences were similarly linked to amyloid biomarkers, brain inflammation, and reduced grey matter, but only in people with a history of psychiatric problems. This might be because people with mental health concerns are more sensitive to the adverse effects of stress. It's also possible that people who have gone through certain stressful life situations are more prone to develop a psychiatric disorder. In either case, people who encounter both may face an elevated danger. Total stressful life experiences were not associated with Alzheimer's disease indicators in all individuals. These findings imply that some periods or settings amplify the effects of stressful life events on the development of Alzheimer's disease-related brain alterations, at least in individuals who are predisposed to the disease. There are certain limits to the results. The researchers depended on participants to recall what and when stressful situations occurred, often several years later. (With inputs from agencies)

Youth and midlife stress events linked to increased dementia risk in later life, study finds

<p>The US Food and Drug Administration (FDA) on Thursday granted standard approval to Leqembi (lecanemab-irmb), a drug intended for the treatment of Alzheimer's disease, however, the decision also presents challenging concerns regarding the safety of the medication and its cost.</p>

<p>Leqembi has a US list price of $26,500 per year.</p>

<p>The decision comes after a confirmatory trial demonstrated clinical benefit, making Leqembi the first amyloid beta-directed antibody to transition from accelerated approval to traditional approval for Alzheimer's disease treatment.&nbsp;</p>

<p>"The drug works by reducing amyloid plaques that form in the brain, a defining pathophysiological feature of the disease," FDA said in a press release.&nbsp;</p>

<h2><strong>Accelerated approval&nbsp;</strong></h2>

<p>Leqembi initially received accelerated approval in January. This approval allows FDA to grant approval for drugs addressing serious conditions with unmet medical needs.&nbsp;</p>

<p>In the case of Leqembi, the drug's ability to reduce amyloid plaques indicated potential clinical benefit. "Efficacy of Leqembi was evaluated using the results of Study 301 (CLARITY AD), a Phase 3 randomised, controlled clinical trial," the statement added.&nbsp;</p>

<p>Also Read | <a href="https://www.wionews.com/world/us-man-found-guilty-of-raping-impregnating-9-year-old-girl-gets-life-sentence-612846">US: Man found guilty of raping, impregnating 9-year-old girl gets life sentence</a></p>

<p>Teresa Buracchio, the acting director of the Office of Neuroscience in the FDA's Center for Drug Evaluation and Research, said, “Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease."&nbsp;</p>

<p>“This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease," the official added.&nbsp;</p>

<h2><strong>Alzheimer's disease&nbsp;</strong></h2>

<p>Alzheimer's disease is an irreversible, progressive brain disorder affecting over 6.5 million Americans. It leads to memory loss, impaired thinking skills, and the inability to carry out simple tasks.&nbsp;</p>

<p>Also Read | <a href="https://www.wionews.com/world/hong-kong-police-arrest-four-men-for-allegedly-aiding-overseas-activists-612850">Hong Kong police arrest four men for allegedly aiding overseas activists</a></p>

<p>Although the precise causes remain uncertain, the disease is characterised by changes in the brain, including the formation of amyloid beta plaques and neurofibrillary tangles, which result in the loss of neurons and their connections.</p>

<h2><strong>Study 301&nbsp;</strong></h2>

<p>Study 301 enrolled 1,795 patients with Alzheimer's disease, focusing on those in the mild cognitive impairment or mild dementia stage with confirmed amyloid beta pathology.&nbsp;</p>

<p>Participants were randomly assigned to receive a placebo or a Leqembi dose of 10 mg/kg&nbsp;body weight every two weeks.&nbsp;</p>

<p><strong>Watch | Russian expert claims the US is working on weaponising asteroids against enemies</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/russian-expert-claims-the-us-is-working-on-weaponising-asteroids-against-their-enemies-612836/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>"Leqembi demonstrated a statistically significant and clinically meaningful reduction of decline from baseline to 18 months on the primary endpoint, the Clinical Dementia Rating Scale Sum of Boxes score, compared to placebo," FDA statement said.&nbsp;</p>

<h2><strong>Support from advisory committee, safety considerations</strong></h2>

<p>On June 9, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee reviewed the evidence from Study 301 and voted positively, affirming Leqembi's clinical benefit for treating Alzheimer's disease.</p>

<p>The FDA said the drug’s label will include a “boxed warning” highlighting safety issues. The most common side effects of Leqembi include headache, infusion-related reactions, and amyloid-related imaging abnormalities (ARIA). It may also involve small spots of bleeding in or on the brain's surface.&nbsp;</p>

<p>While ARIA is often asymptomatic, FDA said, it can cause symptoms such as headache, confusion, dizziness, vision changes, and nausea.&nbsp;</p>

<p>According to Medicare's announcement on Thursday, the FDA's decision will result in the drug becoming accessible to a wider range of individuals.</p>

<p>Previously, Medicare, the health programme for older Americans, did not cover the cost of the drug beyond clinical trials following its accelerated approval.</p>

<p>However, Medicare has now stated that the treatment will be covered once it receives complete FDA approval, on the condition that healthcare providers participate in registries that gather information about the real-world effectiveness of Leqembi.</p>

<p>The approval of Leqembi was granted to Eisai Inc, FDA said.&nbsp;</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<p><strong>WATCH WION LIVE HERE</strong></p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></p>

<p>You can <strong>now write for wionews.com</strong> and be a part of the community. Share your stories and opinions with us <strong><a href="https://www.wionews.com/content-contribution-registration-form">here</a>.</strong></p>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>


The US Food and Drug Administration (FDA) on Thursday granted standard approval to Leqembi (lecanemab-irmb), a drug intended for the treatment of Alzheimer's disease, however, the decision also presents challenging concerns regarding the safety of the medication and its cost.

The US Food and Drug Administration (FDA) on Thursday granted standard approval to Leqembi (lecanemab-irmb), a drug intended for the treatment of Alzheimer's disease, however, the decision also presents challenging concerns regarding the safety of the medication and its cost. Leqembi has a US list price of $26,500 per year. The decision comes after a confirmatory trial demonstrated clinical benefit, making Leqembi the first amyloid beta-directed antibody to transition from accelerated approval to traditional approval for Alzheimer's disease treatment. "The drug works by reducing amyloid plaques that form in the brain, a defining pathophysiological feature of the disease," FDA said in a press release. Accelerated approval Leqembi initially received accelerated approval in January. This approval allows FDA to grant approval for drugs addressing serious conditions with unmet medical needs. In the case of Leqembi, the drug's ability to reduce amyloid plaques indicated potential clinical benefit. "Efficacy of Leqembi was evaluated using the results of Study 301 (CLARITY AD), a Phase 3 randomised, controlled clinical trial," the statement added. Also Read | US: Man found guilty of raping, impregnating 9-year-old girl gets life sentence Teresa Buracchio, the acting director of the Office of Neuroscience in the FDA's Center for Drug Evaluation and Research, said, “Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease." “This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease," the official added. Alzheimer's disease Alzheimer's disease is an irreversible, progressive brain disorder affecting over 6.5 million Americans. It leads to memory loss, impaired thinking skills, and the inability to carry out simple tasks. Also Read | Hong Kong police arrest four men for allegedly aiding overseas activists Although the precise causes remain uncertain, the disease is characterised by changes in the brain, including the formation of amyloid beta plaques and neurofibrillary tangles, which result in the loss of neurons and their connections. Study 301 Study 301 enrolled 1,795 patients with Alzheimer's disease, focusing on those in the mild cognitive impairment or mild dementia stage with confirmed amyloid beta pathology. Participants were randomly assigned to receive a placebo or a Leqembi dose of 10 mg/kg body weight every two weeks. Watch | Russian expert claims the US is working on weaponising asteroids against enemies × "Leqembi demonstrated a statistically significant and clinically meaningful reduction of decline from baseline to 18 months on the primary endpoint, the Clinical Dementia Rating Scale Sum of Boxes score, compared to placebo," FDA statement said. Support from advisory committee, safety considerations On June 9, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee reviewed the evidence from Study 301 and voted positively, affirming Leqembi's clinical benefit for treating Alzheimer's disease. The FDA said the drug’s label will include a “boxed warning” highlighting safety issues. The most common side effects of Leqembi include headache, infusion-related reactions, and amyloid-related imaging abnormalities (ARIA). It may also involve small spots of bleeding in or on the brain's surface. While ARIA is often asymptomatic, FDA said, it can cause symptoms such as headache, confusion, dizziness, vision changes, and nausea. According to Medicare's announcement on Thursday, the FDA's decision will result in the drug becoming accessible to a wider range of individuals. Previously, Medicare, the health programme for older Americans, did not cover the cost of the drug beyond clinical trials following its accelerated approval. However, Medicare has now stated that the treatment will be covered once it receives complete FDA approval, on the condition that healthcare providers participate in registries that gather information about the real-world effectiveness of Leqembi. The approval of Leqembi was granted to Eisai Inc, FDA said. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here. ×

FDA grants standard approval for Alzheimer's drug, Leqembi, despite lingering concerns

<p>Regular physical exercise, particularly resistance training, can help prevent Alzheimer's disease or delay the onset of symptoms, a recent study suggests. The study wase published in Frontiers in Neuroscience by Brazilian researchers from the Federal University of Sao Paulo (UNIFESP) and the University of Sao Paulo (USP).&nbsp;</p>

<p>To understand the effects of resistance training, the researchers conducted experiments using transgenic mice that had a mutation leading to the accumulation of beta-amyloid plaques in the brain, a characteristic feature of Alzheimer's disease.&nbsp;</p>

<p>The buildup of these plaques impairs synaptic connections, damages neurons, and contributes to Alzheimer's symptoms.&nbsp;</p>

<p>The mice were trained to climb a ladder with weights attached to their tails, simulating resistance training similar to what humans do in fitness centres. As part of the research, the mice underwent a training regimen involving climbing a 110 cm ladder with an 80° slope and rungs spaced 2 cm apart.&nbsp;</p>

<p>Also Read | <a href="https://www.wionews.com/world/discovery-of-cocaine-in-white-house-library-prompts-secret-service-investigation-611984">Discovery of cocaine in White House library prompts secret service investigation</a></p>

<p>To simulate resistance training commonly performed by humans in fitness centres, weights were attached to the mice's tails, representing 75%, 90%, and 100% of their body weight.</p>

<h2><strong>Positive results&nbsp;</strong></h2>

<p>After a four-week period of training, blood samples were taken from the mice to measure plasma levels of corticosterone, the hormone equivalent to cortisol in humans.&nbsp;</p>

<p>Elevated levels of this hormone are associated with increased Alzheimer's risk. The exercise-trained mice showed normal hormone levels.&nbsp;</p>

<p>Also Read | <a href="https://www.wionews.com/world/israeli-military-is-completing-mission-in-west-bank-says-pm-netanyahu-death-toll-in-jenin-rises-to-11-611977">Israeli military is ‘completing mission’ in West Bank, says PM Netanyahu; death toll in Jenin rises to 11</a></p>

<p>Furthermore, analysis of their brain tissue revealed a decrease in the formation of beta-amyloid plaques.&nbsp;</p>

<p>These findings indicate that physical activity can reverse the neuropathological changes that lead to clinical symptoms of Alzheimer's.</p>

<h2><strong>Behavioral benefits, reduction of anxiety</strong></h2>

<p>The researchers also assessed the animals' behaviour, particularly their anxiety levels in an open field test. Alzheimer's and other dementia types often manifest symptoms such as agitation and restlessness.&nbsp;</p>

<p>The mice that underwent resistance exercise exhibited reduced hyperlocomotion. This suggests that resistance exercise may help alleviate these early symptoms associated with Alzheimer's disease.</p>

<p>“The main possible reason for this effectiveness is the anti-inflammatory action of resistance exercise,” said Beatriz Monteiro Longo, last author of the article and a professor of neurophysiology at UNIFESP.&nbsp;</p>

<p><strong>WATCH | Gravitas: Russia says Ukraine attacked Moscow with 5 drones</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-russia-says-ukraine-attacked-moscow-with-5-drones-611978/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>The World Health Organization (WHO) recommends resistance exercise as an ideal option for improving balance, posture, and preventing falls.&nbsp;</p>

<p>This form of exercise involves contracting specific muscles against external resistance and offers various benefits such as increasing muscle mass, strength and functional capacity.</p>

<p>Resistance exercise also plays a role in preventing or mitigating sarcopenia (muscle atrophy), which can make everyday tasks easier to perform.</p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<p><strong>WATCH WION LIVE HERE</strong></p>

<p><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></p>

<p>You can <strong>now write for wionews.com</strong> and be a part of the community. Share your stories and opinions with us <strong><a href="https://www.wionews.com/content-contribution-registration-form">here</a>.</strong></p>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>&nbsp;</p>


Regular physical exercise, particularly resistance training, can help prevent Alzheimer's disease or delay the onset of symptoms, a recent study suggests. The study wase published in Frontiers in Neuroscience by Brazilian researchers from the Federal University of Sao Paulo (UNIFESP) and the University of Sao Paulo (USP).

Regular physical exercise, particularly resistance training, can help prevent Alzheimer's disease or delay the onset of symptoms, a recent study suggests. The study wase published in Frontiers in Neuroscience by Brazilian researchers from the Federal University of Sao Paulo (UNIFESP) and the University of Sao Paulo (USP). To understand the effects of resistance training, the researchers conducted experiments using transgenic mice that had a mutation leading to the accumulation of beta-amyloid plaques in the brain, a characteristic feature of Alzheimer's disease. The buildup of these plaques impairs synaptic connections, damages neurons, and contributes to Alzheimer's symptoms. The mice were trained to climb a ladder with weights attached to their tails, simulating resistance training similar to what humans do in fitness centres. As part of the research, the mice underwent a training regimen involving climbing a 110 cm ladder with an 80° slope and rungs spaced 2 cm apart. Also Read | Discovery of cocaine in White House library prompts secret service investigation To simulate resistance training commonly performed by humans in fitness centres, weights were attached to the mice's tails, representing 75%, 90%, and 100% of their body weight. Positive results After a four-week period of training, blood samples were taken from the mice to measure plasma levels of corticosterone, the hormone equivalent to cortisol in humans. Elevated levels of this hormone are associated with increased Alzheimer's risk. The exercise-trained mice showed normal hormone levels. Also Read | Israeli military is ‘completing mission’ in West Bank, says PM Netanyahu; death toll in Jenin rises to 11 Furthermore, analysis of their brain tissue revealed a decrease in the formation of beta-amyloid plaques. These findings indicate that physical activity can reverse the neuropathological changes that lead to clinical symptoms of Alzheimer's. Behavioral benefits, reduction of anxiety The researchers also assessed the animals' behaviour, particularly their anxiety levels in an open field test. Alzheimer's and other dementia types often manifest symptoms such as agitation and restlessness. The mice that underwent resistance exercise exhibited reduced hyperlocomotion. This suggests that resistance exercise may help alleviate these early symptoms associated with Alzheimer's disease. “The main possible reason for this effectiveness is the anti-inflammatory action of resistance exercise,” said Beatriz Monteiro Longo, last author of the article and a professor of neurophysiology at UNIFESP. WATCH | Gravitas: Russia says Ukraine attacked Moscow with 5 drones × The World Health Organization (WHO) recommends resistance exercise as an ideal option for improving balance, posture, and preventing falls. This form of exercise involves contracting specific muscles against external resistance and offers various benefits such as increasing muscle mass, strength and functional capacity. Resistance exercise also plays a role in preventing or mitigating sarcopenia (muscle atrophy), which can make everyday tasks easier to perform. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here. ×

Resistance training: A promising measure to prevent, delay Alzheimer's

A new Alzheimer’s drug slowed cognitive decline by 35%, according to late-stage trial results, raising the prospect of a second effective treatment for the disease. WION tells you more in this report.

Beginning of an end to Alzheimer's?